# Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma

> **NCT00535314** · PHASE2 · WITHDRAWN · sponsor: **Biogen**

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** RTA 402 Dose1
- **DRUG:** RTA 402 Dose2

## Key facts

- **NCT ID:** NCT00535314
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2025-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00535314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00535314, "Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00535314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*